
COGNO: Cooperative Trials Group for Neuro-Oncology

The achievement of better health outcomes for patients and those affected by brain tumours through clinical trials research

27 September 2013

Dr Brendan Shaw
Chief Executive
Medicines Australia
Level 1
16 Napier Close
DEAKIN ACT 2600

Dear Dr Shaw

Re: Access to Cancer Medicines in Australia Report

Thank you for your letter of 30 August 2013, addressed to Professor Simes, seeking feedback from COGNO on the initial findings of the Deloitte Access Economics Report, *Access to Cancer Medicines in Australia*.

COGNO supports the access, availability and use of new medicines based on suitable clinical trial evidence regarding their effectiveness. Importantly, COGNO recommends that the cost-effectiveness and net clinical benefit of such treatments be evaluated from the patient's perspective (and their families); as well as a community perspective.

Kind regards

Yours sincerely



Professor Mark Rosenthal
Chair, COGNO